MK-4700 + pembrolizumab

MK-4700 + pembrolizumab is an investigational combination therapy currently being studied for the treatment of advanced or metastatic solid tumors, including specific subtypes of kidney cancer (clear cell or papillary forms) and a range of other malignancies. MK-4700 is an experimental agent with an undisclosed mechanism, while pembrolizumab (Keytruda; MK-3475) is a humanized monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor, leading to immune system reactivation against cancer cells. The combination is administered to explore additive or synergistic anti-tumor activity, measured primarily in terms of safety, tolerability, and preliminary efficacy in early-phase clinical trials[1][3][5][7].

Other names

MK-4700 + KeytrudaMK-4700 + MK-3475